Page last updated: 2024-11-07

8-bromoadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

8-Bromoadenosine (8-Br-Ado) is a synthetic adenosine analog that acts as a potent and selective adenosine A1 receptor agonist. It is widely used in research to study the role of adenosine in various physiological processes, including neurotransmission, inflammation, and cardiovascular function. 8-Br-Ado is typically synthesized through a multi-step process involving bromination of adenosine with bromine in the presence of a suitable solvent. The compound is known to exhibit a number of effects, such as inhibiting neuronal firing, reducing inflammation, and lowering blood pressure. Its ability to mimic adenosine's effects makes it a valuable tool for studying the role of adenosine in various disease states, such as Parkinson's disease, Alzheimer's disease, and cancer. Researchers often utilize 8-Br-Ado to investigate the therapeutic potential of targeting the adenosine A1 receptor in these conditions.'

Cross-References

ID SourceID
PubMed CID96544
CHEMBL ID1775009
CHEBI ID2312
SCHEMBL ID440925
MeSH IDM0110036

Synonyms (39)

Synonym
(2r,3r,4s,5r)-2-(6-amino-8-bromo-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
adenosine, 8-bromo
8-bromo-adenosine
adenosine, 8-bromo-
nsc-79213
bromoadenosine
2946-39-6
8-bromoadenosine
8-bromoadenosine, powder
6-amino-8-bromopurine riboside
AKOS001715167
CHEMBL1775009 ,
chebi:2312 ,
(4s,2r,3r,5r)-2-(6-amino-8-bromopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2r,3r,4s,5r)-2-(6-amino-8-bromo-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
A819926
8-bromoadenine-9-beta-d-ribofuranoside
einecs 220-959-0
85c9t4txh2 ,
nsc 79213
unii-85c9t4txh2
AM84901
GBA ,
HG1277
8-bromo adenosine
SCHEMBL440925
VJUPMOPLUQHMLE-UUOKFMHZSA-N
bdbm50454084
mfcd00005733
8-bromadenosine
sr-01000147759
SR-01000147759-1
DS-4670
Q27105621
(2r,3r,4s,5r)-2-(6-amino-8-bromo-9h-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
EN300-212333
DTXSID001021364
Z2065682349
BP-58688
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID70685Optimum concentration for the extent of differentiation of friend erythroleukemia cells was evaluated.(deoxy-coformycin added at 25 uM)1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID597360Inhibition of human recombinant GST-tagged SIRT1 at 50 uM after 4 hrs by homogeneous fluorescent deacetylase assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD).
AID70684Inhibition of Cellular Replication of friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID33205Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat Adenosine A3 receptor1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID597363Inhibition of human recombinant N-terminally His6-tagged SIRT2 at 50 uM after 4 hrs by homogeneous fluorescent deacetylase assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD).
AID70562Percent benzidine-positive cells in friend erythroleukemia cells was evaluated (deoxy-coformycin added at 25 uM)1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID70686Optimum concentration for differentiation of friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID33911Affinity constant for A2 receptor control of adenylate cyclase in adipocytes, heart and brain cells; Inactive1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID1151015Activity at rabbit muscle AMP aminohydrolase after 24 hrs by Lineweaver-Burk plot analysis relative to AMP1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Design of substrate-site-directed irreversible inhibitors of adenosine 5'-phosphate aminohydrolase. Effect of substrate substituents on affinity for the substrate site.
AID1151008Activity at rabbit muscle AMP aminohydrolase by Lineweaver-Burk plot analysis1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Design of substrate-site-directed irreversible inhibitors of adenosine 5'-phosphate aminohydrolase. Effect of substrate substituents on affinity for the substrate site.
AID70559Percent benzidine-positive cell differentiation in friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID70683Compound was evaluated for the inhibition of Cellular Replication (deoxy-coformycin added at 25 uM)1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID30355Inhibitory constant against A1 receptor control of adenylate cyclase in adipocytes, heart and brain cells; Inactive1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID33792Binding affinity to adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID31247Binding affinity determined on Adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID34158Inhibition of adenyl cyclase via P site in adipocytes; Inactive1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (24.24)18.7374
1990's11 (33.33)18.2507
2000's7 (21.21)29.6817
2010's6 (18.18)24.3611
2020's1 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.90 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index19.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (96.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]